Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
FDA released final guidance on assessing adhesion for transdermal and topical delivery systems in ANDAs, affecting generic drug developers and manufacturers.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on August 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Generic drug manufacturers developing transdermal and topical delivery systems for ANDAs. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline; guidance is effective immediately.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New FDA guidance on methods for assessing adhesion of these products.
Who it affects
Generic drug manufacturers developing transdermal and topical delivery systems for ANDAs.
What you must do
Review the guidance and update development/testing protocols accordingly.
Deadline
No specific deadline; guidance is effective immediately.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- US-CONGRESS HR1266: Combating Illicit Xylazine Act
- Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court - kff.org
- Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
- Prisma Health Midlands to Pay $1 Million to Resolve Alleged Controlled Substance Act Violations - DEA.gov
- Utah opens applications for another medical cannabis license - mjbizdaily.com